In terms of market share, India’s fourth largest pharmaceutical pharmaceutical pharma is now focusing on peptide and serious remedies such as Peptide-1 (GLP) like Glucagon, such as Glucagon and serious remedies. The lead pharma company is now preparing to come with Novo Nordisk’s strong drug Semaglutide with its generic variants, which will be freed from the patent next year.
Atish Mazumdar, senior president of Mankind Specialty (Sales and Marketing), said that he is expected to introduce generic semaglutide next year and will try to present his variant soon. Majumdar believes that this will significantly reduce the prices of this category of medicines. Currently, the price of GLP-1 category drugs for the entire month’s course is between 40 and 50 thousand rupees.
It is generally seen that after the patent is over, the prices of the innovator drug decrease by about 30 to 40 percent and then the prices gradually start to decrease and eventually it is reduced by about 75 to 80 percent of the original price. She goes. Majumdar said that obesity has now become the center of discussion around the world and generic medicines will start rapidly after the patent is over.
First Published – February 26, 2025 | 10:21 pm IST